NJ Heart
Linden, New Jersey, United States
Cardiologist in Linden, New Jersey
520 N Wood Ave, Linden, NJ 07036
About NJ Heart
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Bayer
2
Gilead Sciences
2
Pfizer
2
Brigham and Women's Hospital
1
Bristol-Myers Squibb
1
Duke University
1
Eisai Inc.
1
Eli Lilly and Company
1
HealthCore-NERI
1
Kowa Research Institute, Inc.
1
Novartis Pharmaceuticals
1
Clinical Trials at NJ Heart
During the past decade, NJ Heart conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 6 clinical trials were completed, i.e. on
average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
2006-08-01
2013-06-01
Completed
3,445
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
2007-05-01
2010-05-01
Terminated
661
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
2006-09-01
2009-08-01
Completed
849
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
2013-10-29
2017-03-22
Terminated
16,784
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
2013-10-29
2017-04-03
Terminated
10,564
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
2014-01-24
2018-05-14
Completed
14,673
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
2015-06-04
2018-11-10
Completed
4,614
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "NJ Heart" #1 sponsor was "Bayer" with 2 trials, followed by "Gilead Sciences" with 2 trials
sponsored, "Pfizer" with 2 trials sponsored, "Brigham and Women's Hospital" with 1 trials sponsored and "Bristol-Myers Squibb"
with 1 trials sponsored. Other sponsors include 2 different institutions and
companies that sponsored additional 12 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "NJ Heart"
#1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 7 trials.
Clinical Trials Conditions at NJ Heart
According to Clinical.Site data, the most researched conditions in "NJ Heart" are
"Cardiovascular Disease" (4 trials), "Cardiovascular Diseases" (2 trials), "Heart Failure" (2 trials), "Hypertension" (2 trials) and "Obesity" (2 trials). Many other conditions were trialed in "NJ Heart" in a lesser frequency.
Clinical Trials Intervention Types at NJ Heart
Most popular intervention types in "NJ Heart" are "Drug" (13 trials), "Other" (3 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (9 trials), "Apixaban" (2 trials), "Darusentan" (2 trials), "Guanfacine" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.
Clinical Trials Genders at NJ Heart
The vast majority of trials in "NJ Heart" are
15 trials for "All" genders.
Clinical Trials Status at NJ Heart
Currently, there are NaN active trials in "NJ Heart".
undefined are not yet recruiting,
3 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 5 completed trials in NJ Heart,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in NJ Heart, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 11 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 2 trials that are defined as “Not Applicable".